Trevi Therapeutics TRVI
NASDAQ TRVI
$14.91 -0.40 (-2.61%)
At close: Nov 10, 2026 · 4:00 PM EST

Trevi Therapeutics (TRVI) Preferred Stock Liabilities (2018 - 2019)

Updated

Trevi Therapeutics (TRVI) posted Preferred Stock Liabilities of $128.15 million for Q1 2019, down 60.7% from the prior quarter.

Analysis

Trevi Therapeutics (TRVI) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

At the end of FY2018, Trevi Therapeutics' Preferred Stock Liabilities came in at $326.19 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Trevi Therapeutics 2.13 Bn 1.15 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 61.02 Mn
Sep 30, 2019 61.02 Mn
Jun 30, 2019 61.02 Mn
Mar 31, 2019 128.15 Mn
Dec 31, 2018 326.19 Mn
API Access

Trevi Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=TRVI&period=max&api_key=YOUR_API_KEY